Lodi Valley News.com

Complete News World

Janssen vaccine may not protect against Covid, French study suggests - 09/14/2021 - Balance and Health

Janssen vaccine may not protect against Covid, French study suggests – 09/14/2021 – Balance and Health

After distrust with AstraZeneca, which raises Rare cases of pulmonary embolismIs it time for the French people to avoid Janssen? The question comes after a French study revealed that protection from a single dose of the Covid vaccine would not be enough.

The survey was carried out by the pharmacovigilance centers in Lyon and Grenoble and published by the National Agency for the Safety of Medicines on Tuesday (14).

The report cites a “significant number of vaccine failures” in Johnson & Johnson Immunization Agent, mainly against delta variable. With the data available to date, the long-term efficacy of this vaccine cannot be confirmed.

From July 9 to August 26, the two French Centers for Pharmacovigilance are tasked with monitoring Janssen’s side effects.

The data collected detail the role the immunizing agent played, or not, in the onset of different symptoms, more or less severe, such as trumpetFacial paralysis, stroke, seizures, and others.

At this point, the balance is positive. The document indicates that “these side effects are isolated and do not indicate a specific role for the antiviral vaccine and so far there is no direct relationship between Janssen and the deaths recorded in the country.”

But given the large number of people who took a single dose of the vaccine and were later admitted to intensive care units with Covid-19, the French agency notes a potential risk of immune system failure.

The report emphasized that these patients suffer or suffer from severe comorbidities. They were hospitalized more than 21 days after they were vaccinated. New investigations are underway.

See also  CamaquĆ£ ends week with asset cuts and hospitalizations with Covid-19

The large proportion of people who received Janssen, contracted coronavirus and required intensive care, is alarming.

In Marseille, of the seven fully vaccinated patients who were admitted to resuscitation service during the research period, four received a Johnson & Johnson immunization agent. In Tours, that proportion was three out of six inpatients.

By the end of August, 1 million doses of Janssen vaccine had been administered in France. Of the people who received the single injection, 32 cases of Covid-19 were reported, which represents a rate of 3.78 per 100,000.

Of those infected, 29 became seriously ill, and four died. The ages of the victims ranged between 73 and 87 years.

Health authorities are not aware of the variant responsible for contamination in about half of the cases, but of the 17 known cases, all were caused by the delta variant.

Janssen offers the advantage of getting a single dose, but since late August, France’s top health authority has recommended that people be vaccinated with Johnson & Johnson. Receiving a second dose of a mRNA-based immune system, either from Pfizer or Moderna. The recommendation was accepted by the French Ministry of Health.

Infectious disease specialist Benjamin Davido, who was heard by Le Parisien, considered Janssen’s case not exceptional.

“There is no vaccine or breakthrough treatment that provides long-term immunity against colds or infection of the coronavirus family,” the expert recalls.